Literature DB >> 23664855

A nationwide study of comorbidity and risk of reinfection after Staphylococcus aureus bacteraemia.

L Wiese1, N Mejer, H C Schønheyder, H Westh, A G Jensen, A R Larsen, R Skov, T Benfield.   

Abstract

BACKGROUND: Data on risk factors and rates of reinfection associated with Staphylococcus aureus bacteraemia (SAB) are sparse.
METHODS: We conducted a nationwide cohort study of cases of SAB diagnosed between 1995 and 2008. Reinfection was defined as an episode of SAB more than 90 days after the initial episode of SAB. Comorbidity was evaluated by the Charlson Comorbidity Index (CCI). Cox proportional hazards modelling was used to estimate hazard rates (HR).
RESULTS: Of 10,891 eligible patients, 774 (7.1%) experienced reinfection a median of 458 days (range 90-5021 days) after their primary SAB episode corresponding to a reinfection rate of 1459 (95% confidence interval (CI): 1357-1562) per 100,000 personyears. In multivariate analysis, sex, origin, a vascular or peritoneal device, endocarditis and comorbidity were associated with reinfection. The association was more than two-fold higher among patients in dialysis and for patients with severe comorbidity (CCI ≥ 2). HIV infection (Hazard ratio (HR) 6.18, 95% CI: 4.17-9.16), renal disease (HR 3.92, 95% CI: 3.22-4.78), diabetes with complications (HR 2.11, 95% CI: 1.69-2.62), diabetes without complications (HR 1.61, 95% CI: 1.34-1.93), mild (HR: 1.94, 95% CI: 1.36-2.76) and severe liver disease (HR 2.08, 95% CI: 1.08-4.03), peptic ulcer (HR 1.33, 95% CI: 1.03-1.72), and paraplegia (HR 2.15, 95% CI: 1.02-4.54) were each associated with an increased risk of reinfection.
CONCLUSIONS: Patients with previous SAB have a 60-fold higher risk of SAB compared to the general population. Patients with HIV infection, renal disease, diabetes, liver disease, peptic ulcer and paraplegia had the highest rates of reinfection.
Copyright © 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bacteraemia; CA; CAPD; CCI; CI; Charlson Comorbidity Index; Comorbidity; Epidemiology; HA; HIV; Incidence; MRSA; Mortality; PYFU; Recurrence; Reinfection; SAB; Staphylococcus aureus; Staphylococcus aureus bacteraemia; community-acquired; confidence interval; continuous ambulatory peritoneal dialysis; hospital-associated; human immunodeficiency virus; methicillin-resistant Staphylococcus aureus; personyears of follow-up

Mesh:

Year:  2013        PMID: 23664855     DOI: 10.1016/j.jinf.2013.04.018

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  16 in total

1.  Genotyping of methicillin-resistant Staphylococcus aureus from sepsis patients in Pakistan and detection of antibodies against staphylococcal virulence factors.

Authors:  Stefan Monecke; Muhammad Ali Syed; Mushtaq Ahmad Khan; Shehzad Ahmed; Sadia Tabassum; Darius Gawlik; Elke Müller; Annett Reissig; Sascha D Braun; Ralf Ehricht
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-03       Impact factor: 3.267

2.  Activation of Human Vδ2+ γδ T Cells by Staphylococcus aureus Promotes Enhanced Anti-Staphylococcal Adaptive Immunity.

Authors:  Andrew J R Cooper; Stephen J Lalor; Rachel M McLoughlin
Journal:  J Immunol       Date:  2020-07-10       Impact factor: 5.422

3.  Methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia in haemodialysis patients.

Authors:  Guillermo Cuervo; Mariana Camoez; Evelyn Shaw; María Ángeles Dominguez; Oriol Gasch; Belén Padilla; Vicente Pintado; Benito Almirante; José Molina; Francisco López-Medrano; Enrique Ruiz de Gopegui; José A Martinez; Elena Bereciartua; Fernando Rodriguez-Lopez; Carlos Fernandez-Mazarrasa; Miguel Ángel Goenaga; Natividad Benito; Jesús Rodriguez-Baño; Elena Espejo; Miquel Pujol
Journal:  BMC Infect Dis       Date:  2015-10-30       Impact factor: 3.090

4.  Outcome and reinfection after Staphylococcus aureus bacteraemia in individuals with and without HIV-1 infection: a case-control study.

Authors:  Bianca Stammler Jaliff; Jenny Dahl-Knudsen; Andreas Petersen; Robert Skov; Thomas Benfield
Journal:  BMJ Open       Date:  2014-04-23       Impact factor: 2.692

Review 5.  The Role of Staphylococcus aureus Virulence Factors in Skin Infection and Their Potential as Vaccine Antigens.

Authors:  Keenan A Lacey; Joan A Geoghegan; Rachel M McLoughlin
Journal:  Pathogens       Date:  2016-02-17

6.  Outcome of Community-Acquired Staphylococcus aureus Bacteraemia in Patients with Diabetes: A Historical Population-Based Cohort Study.

Authors:  Jesper Smit; Reimar Wernich Thomsen; Henrik Carl Schønheyder; Henrik Nielsen; Trine Frøslev; Mette Søgaard
Journal:  PLoS One       Date:  2016-04-15       Impact factor: 3.240

7.  Chronic heart failure and mortality in patients with community-acquired Staphylococcus aureus bacteremia: a population-based cohort study.

Authors:  Jesper Smit; Kasper Adelborg; Reimar Wernich Thomsen; Mette Søgaard; Henrik Carl Schønheyder
Journal:  BMC Infect Dis       Date:  2016-05-25       Impact factor: 3.090

8.  The T Cell Response to Staphylococcus aureus.

Authors:  Barbara M Bröker; Daniel Mrochen; Vincent Péton
Journal:  Pathogens       Date:  2016-03-17

9.  The effect of diabetes mellitus on outcomes of patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: data from a prospective double-blind clinical trial comparing treatment with linezolid versus vancomycin.

Authors:  Ozlem Equils; Christopher da Costa; Michele Wible; Benjamin A Lipsky
Journal:  BMC Infect Dis       Date:  2016-09-06       Impact factor: 3.090

10.  Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection.

Authors:  Aisling F Brown; Alison G Murphy; Stephen J Lalor; John M Leech; Kate M O'Keeffe; Micheál Mac Aogáin; Dara P O'Halloran; Keenan A Lacey; Mehri Tavakol; Claire H Hearnden; Deirdre Fitzgerald-Hughes; Hilary Humphreys; Jérôme P Fennell; Willem J van Wamel; Timothy J Foster; Joan A Geoghegan; Ed C Lavelle; Thomas R Rogers; Rachel M McLoughlin
Journal:  PLoS Pathog       Date:  2015-11-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.